Workshop course

Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record attendance and circulation of virtual content for Pharmacometrics Spring School 2022 using MonolixSuite. New for 2022 was the introduction of “NCA, Bioequivalence and Beyond!” “Spring School” course with PKanalix. Both workshops took place in March 2022.

This year’s spring schools focused on population modeling for model-based drug development (MIDD) and clinical trial simulations using MonolixSuite, and PK data analysis at using non-compartmental analysis (NCA) and bioequivalence (BE) calculations using the PKanalix platform. These courses, which were free to the pharmacometrics community, included both theoretical discussions and practical sessions.

In total, there were 936 participants from over 50 countries. Participants were industry professionals from regulatory agencies, pharmaceutical companies, biotechnology companies and CROs, as well as students and doctoral/postdoctoral researchers, from different backgrounds, who used the skills taught in these courses to make their modeling and simulation work more powerful and efficient. .

Dr. Jonathan Chauvin, Lixoft Division President at Simulations Plus, said: “The positive feedback and momentum from our first spring school in 2021 has continued into this year’s program, further confirming the need to provide the pharmacometrics community with quality equipment and training. . As a leader in providing Modeling and Simulation (M&S) software tools and services to support industry and our customers in their efforts to leverage M&S for more efficient drug development, we have been very pleased with the strong interest and support from the user community, and we look forward to offering our pharmacometrics workshops again in 2023.”

About Simulation Plus

Serving customers worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market, providing software and consulting services supporting drug discovery, development, research and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and enforced by leading pharmaceutical, biotechnology and regulatory agencies around the world. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | Youtube.

Environment, Social and Governance (ESG)

We focus our environmental, social and governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG report.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 – Except for historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe”, “expect” and “anticipate” mean that these are our best estimates at the time of writing, but there can be no guarantee that the results or expected or anticipated events will actually occur, which could cause our actual future results to differ materially from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and enhanced versions of our existing software by our customers, the general economic of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical personnel, our ability to identify and complete acquisitions on favorable terms for the Company and a sustainable market. Further information about our risk factors is contained in our quarterly and annual reports and filed with the United States Securities and Exchange Commission.